No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $20
Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutic | 10-K: FY2024 Annual Report
Sonnet BioTherapeutics FY 2024 GAAP EPS $(11.35)
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Express News | Sonnet Biotherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Unlock the Full List